Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
H de Lavallade, M Mohty, C Faucher, S Furst, J El-Cheikh, D Blaise
Haematologica January 2006 91: 1438-1440; doi:

Author Affiliations

  1. H de Lavallade,
  2. M Mohty,
  3. C Faucher,
  4. S Furst,
  5. J El-Cheikh and
  6. D Blaise

Abstract

This study investigated the use of low dose methotrexate (MTX) (5 mg/m2/infusion) for the treatment of graft-versus-host disease (GVHD), after failure of corticosteroids. Twelve patients had refractory acute GVHD, while eight received MTX for severe chronic GVHD and/or the side effects of corticosteroids. Thirteen patients responded to MTX with six complete remissions and little toxicity, suggesting that low dose MTX is beneficial in refractory GVHD and deserves further investigations.

Back to top
Email
Citation Tools

Jump To